top of page
BA7A34C6-C12B-4A28-8C3E-D3C098A28B19.jpeg

 Peer Reviewed Studies

We are currently collating sources of the latest research and peer reviewed publications about HSCT. We will add new articles as soon as we find them. Articles are displayed in descending order by publication date and you can filter the results using the drop down list below

February

2024

Experiences of being treated with autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: A qualitative interview study

Plos One

February

2024

Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial

Pubmed

February

2024

Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: Sustained improvement in cognition and quality of life

Pubmed

July

2023

Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

Pubmed

July

2023

B cell depletion therapy does not resolve chronic active multiple sclerosis lesions

The Lancet

May

2023

Long-term results of autografting persons with multiple sclerosis are better in those not exposed to prior disease-modifying therapies

Multiple Sclerosis & Related Disorders

December

2022

Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis

PubMed

August

2022

Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT

Pubmed

July

2022

High-dose immunosuppressive therapy with autologous hematopoietic stem cells transplantation for multiple sclerosis: Current view

Cellular Therapy and Transplantation (CTT)

July

2022

Stem Cell Therapy in Neuroimmunological Diseases and Its
Potential Neuroimmunological Complications

Cells

May

2022

Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Nature

February

2022

ACTRIMS2022 – Immune System ‘Reset’ by Stem Cell Transplant (fully myeloablative)

Multiple Sclerosis News Today

February

2022

Blood Stem Cell Transplant May Help Immune System Longer

Multiple Sclerosis News Today

February

2022

HSCT versus cyclophosphamide for progression is no better

The MS Blog

February

2022

Autologous hematopoietic stem cell transplantation vs low-dose immunosuppression in secondary-progressive multiple sclerosis

PubMed

September

2021

Real‑world application of autologous hematopoietic stem cell
transplantation in 507 patients with multiple sclerosis

Journal of Neurology

October

2021

Relapse-independent multiple sclerosis progression under natalizumab

PubMed

September

2021

Splitting the Total Dose of Cyclophosphamide in Two Blocks Apart during the Conditioning of Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Results in Diminished Cardiotoxicity: Experience in 1,000 Patients

PubMed

September

2021

Autologous ATG-free hematopoietic stem cell transplantation for refractory autoimmune rheumatic diseases: a Latin American cohort

PubMed

August

2021


International stem cell tourism: a critical literature review and evidence-based recommendations

Oxford Academic

August

2021

Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series

Pubmed

July

2021

Getting Worse

MSSelfie

July

2021

AHSCT with Low-Intensity conditioning regimens in RRMS. Clinical outcomes and quality of life

AHSCT Russia

July

2021

Autologous hematopoietic stem cell transplantation with low-intensity conditioning regimens in relapsing remitting multiple sclerosis: clinical outcomes and quality of life

Cellular Therapy and Transplantation (CTT)

July

2021

New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis

PubMed

March

2021

Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis

Neurology.org

March

2021

Stem Cell Therapy as a Treatment for Autoimmune Disease-Updates in Lupus, Scleroderma, and Multiple Sclerosis

PubMed

February

2021

Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis

Neurology.org

February

2021

Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)

PubMed

February

2021

Evaluating the clinical effectiveness of autologous haematopoietic stem cell transplantation versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison: an exploratory study from the Autoimmune Diseases Working Party (ADWP) of the European Society of Bone and Marrow Transplantation (EBMT)

PubMed

February

2021

Stem Cell Blood Transfusion Slows the Progression of Relapsing-Remitting Multiple Sclerosis

NeurologyToday

February

2021

Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

Nature

February

2021

General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

PubMed

August

2020

Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study

ClinicalTrials.gov

October

2019

The rise of autologous HCT for autoimmune diseases: what is behind it and what does it mean for the future of treatment? An update on behalf of the EBMT Autoimmune Diseases Working Party

PubMed

September

2019

Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)

Nature

June

2019

A general practitioner's guide to hematopoietic stem-cell transplantation

PubMed

February

2019

Position statement providing general information for patients and carers considering HSCT for severe autoimmune diseases

EBMT.org

January

2019

Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial

PubMed

July

2017

Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis

PubMed

February

2017

NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs

PubMed

July

2015

Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives

PubMed

February

2010

Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases

PubMed

bottom of page